Using Big Data To Improve Medication Use And Safety
Funder
National Health and Medical Research Council
Funding Amount
$851,980.00
Summary
More than 1 in 3 Australians report having 3 or more chronic conditions and the majority of older people now take 5 or more medicines. The safety of medicines on their own, and in combination is therefore an issue of significant importance to Australia. This research will develop and assess data methods to monitor the safety of medicines after they are released on the market and then provide and assess interventions for GPs to support improvements in medicine use.
This application will increase the impact of cancer immunotherapy on disease prevention and treatment, by developing new targets and novel combination immunotherapies. Outcomes will include an improved understanding of the immune reaction with cancer and more effective strategies to prevent cancer spread and safely target and eradicate a larger proportion of established and advanced malignant disease.
Professor Godfrey is an immunologist with a long standing history as a pioneer in the study of a specialised type of white blood cell, known as NKT cells. NKT cells are activated in response to lipid-based molecules that are thought to alert the immune system, via NKT cell activation, to the presence of infectious agents or other abnormalities. A better understanding of how NKT cells function will provide new approaches to battling a broad range of diseases where these cells are implicated, incl ....Professor Godfrey is an immunologist with a long standing history as a pioneer in the study of a specialised type of white blood cell, known as NKT cells. NKT cells are activated in response to lipid-based molecules that are thought to alert the immune system, via NKT cell activation, to the presence of infectious agents or other abnormalities. A better understanding of how NKT cells function will provide new approaches to battling a broad range of diseases where these cells are implicated, including cancer, autoimmunity, allergy and infection.Read moreRead less
Towards HIV And Hepatitis C Elimination: Real-world Trials And Innovations In Disease Surveillance
Funder
National Health and Medical Research Council
Funding Amount
$640,210.00
Summary
Over the next five years I will undertake a program of research centred on developing and implementing strategies to help eliminate hepatitis C and HIV as major public health problems. In particular, I will use innovative monitoring systems and field trials to explore ways to diagnose and treat HIV and hepatitis C in vulnerable populations in a more timely way and study the influence this has on reducing the onward transmission of these infections to others.
Evaluations For Efficient And Effective Public Health Responses To HIV Epidemics
Funder
National Health and Medical Research Council
Funding Amount
$699,190.00
Summary
I will lead studies on evaluating population impact and calculating cost-effectiveness of public health prevention programs for HIV/AIDS epidemics in Asia and Eastern Europe. Return on Investment analyses will inform Ministries of Finance about overall budget allocations. Effectiveness and efficiency evaluations and determining optimal allocations of funding mixes will directly inform Ministries of Health in planning program implementation in 15-20 countries in the region.
Preventing Infectious Disease In Vulnerable Populations: Smarter Surveillance, Enhanced Epidemiology And Targeted Trials
Funder
National Health and Medical Research Council
Funding Amount
$631,010.00
Summary
Vulnerable populations, including people who inject drugs and female sex workers, are susceptible to infectious diseases such as HIV and hepatitis C. Preventing the transmission of these infections presents major challenges. The proposed research will 1) develop innovative approaches to identifying and understanding infectious disease in vulnerable populations; 2) improve our responses by designing and testing new approaches to prevention; and 3) reduce associated morbidity and mortality.